Ligand Pharmaceuticals (LGND) Operating Income Growth (5y) (2015 - 2026)

Ligand Pharmaceuticals (LGND) Operating Income Growth (5y) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Ligand Pharmaceuticals 5.92 Bn 5.14 Bn 48.45 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 29.79%
Dec 31, 2025 -9.55%
Sep 30, 2025 71.09%
Jun 30, 2025 3.53%
Mar 31, 2025 -63.15%
Dec 31, 2024 1.09%
Sep 30, 2024 21.15%
Jun 30, 2024 -35.84%
Mar 31, 2024 -67.52%
Dec 31, 2023 -16.01%
Sep 30, 2023 -33.33%
Jun 30, 2023 -15.19%
Mar 31, 2023 -17.44%
Dec 31, 2022 -22.06%
Sep 30, 2022 -5.64%
Jun 30, 2022 -7.82%
Mar 31, 2022 -26.90%
Dec 31, 2021 14.26%
Sep 30, 2021 23.50%
Jun 30, 2021 63.05%